Asia
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Bharat will conduct Phase IV studies to check real-world efficacy against the virus, while Ocugen says Covaxin will be a valuable tool in helping to end the COVID-19 pandemic.
Not everyone is so confident that Aduhelm will transform the Alzheimer’s drug development landscape.
The first human case of H10N3 avian flu was diagnosed in China in late May. Chinese health authorities claim a low risk of contagion. Learn more about it here.
Shares of Fate climbed nearly 4% in premarket trading after it announced positive interim data from a Phase I study of FT516 for patients with relapsed / refractory B-cell lymphoma.
While several countries rely on Sinovac Biotech to end the pandemic, concerns regarding the shot’s efficacy continue to shroud the vaccine. Currently, it is the second most used vaccine worldwide.
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.
Amgen reunites with Kyowa Kirin on the development and potential commercialization of KHK4083, an atopic dermatitis drug, which impacts nearly 30 million people worldwide.
The latest news in COVID-19 includes support for an investigation into the origins of the virus, a new naming system, and legal discussions of whether employers can mandate vaccination.
The funds will enable Esco that provides life sciences tools and services, to expand its toehold in China and the United States.
PRESS RELEASES